Top Stories
The biotechs are teaming up to discover new treatments for autoimmune and inflammatory diseases.
Alkeus' lead candidate gildeuretinol is in Phase III testing for Stargardt disease.
The new financing plus BARDA backing keep VE303, a live biotherapeutic product using defined consortia of bacteria, on course for a pivotal 2027 readout.
The company plans to start a Phase II kidney transplant trial of LIFE-001 in early 2027.
Actimed in 2021 had outlicensed S-oxprenolol to Faraday for development outside amyotrophic lateral sclerosis.
Conference News
- First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with ...
Increases 2026 Revenue Guidance to a Range of $104M to $108M Conference Call Today at 8:30 a.m. Eastern TimeQUEENSBURY, N.Y.--(BUSINESS WIRE)-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional ...
Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026Cash, cash equivalents and short-term investments of $190.0 million as of Jun...
The Company advanced multiple global oncology and immunology programs toward key clinical and regulatory milestones, with significant pipeline catalysts expected in the second half of 2026Global Phas...
Last participant completed final study visit in the 16-week double-blind period of the pivotal Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia; topline data on track and anticipated...
